Goldman Sachs reiterated its Neutral rating on Bristol Myers Squibb BMY and AstraZeneca AZN. On Friday, AstraZeneca added 0.22% to its value to close the week at $49. Its shares lost all of Friday's gains in today's pre-market trading, however, falling 1.24% to $48.29. At the same time, Bristol Myers lost 1.36% of its value on Friday to finish the week at $28.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: ReiterationAnalyst RatingsAstraZenecabristol myersGoldman SachsHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
